100xOG

[100xOG @100xOG]

$NEXR waking up while the market’s been weak 👀

+20% today with increasing volume on a ~$2M market cap. That’s not normal.

Recent updates picking up + KeepZone AI just got authorization in energy/infrastructure security.

Early narrative forming. High risk, but watching closely

[100xOG @100xOG]

$Nexr anybody? This is going parabolic right now

[100xOG @100xOG]

$SEGG 👀

[100xOG @100xOG]

$SEGG 👀

[@stewdomer @stewdomer]

$SEGG

[Mark Lewis @technoviking_14]

$SEGG GETTING ON IT FOR THE #worldcup

[100xOG @100xOG]

Eyes on $SEGG everyone. This setup is starting to get serious. Strong move while broader market stays red and reclaimed the key $2 level. This is becoming one of the more interesting small-cap momentum plays on the market right now 👀

[100xOG @100xOG]

Eyes on $SEGG everyone. This setup is starting to get serious. Strong move while broader market stays red and reclaimed the key $2 level. This is becoming one of the more interesting small-cap momentum plays on the market right now 👀

[100xOG @100xOG]

$SEGG starting to gain real momentum 🚨‼️

Revenue growth exploding after the Veloce deal, assets now over $125M, and Fintel showing strong volume with rising short interest.

Market bleeding red while SEGG keeps pushing higher. Feels like more eyes are starting to notice this.

[100xOG @100xOG]

$SEGG starting to gain real momentum 🚨‼️

Revenue growth exploding after the Veloce deal, assets now over $125M, and Fintel showing strong volume with rising short interest.

Market bleeding red while SEGG keeps pushing higher. Feels like more eyes are starting to notice this.

[100xOG @100xOG]

$SEGG looking primed 🚨‼️‼️

• $10.3M pro forma revenue
• $125M + assets
• ~1400% revenue growth
• Lando Norris / Quadrant exposure
• Rising short interest + strong volume (Fintel)

Market is red while SEGG keeps running. Could get very interesting fast 📈

[100xOG @100xOG]

$SEGG looking primed 🚨‼️‼️

• $10.3M pro forma revenue
• $125M + assets
• ~1400% revenue growth
• Lando Norris / Quadrant exposure
• Rising short interest + strong volume (Fintel)

Market is red while SEGG keeps running. Could get very interesting fast 📈

[100xOG @100xOG]

$NEXR waking up while the market’s been weak 👀

+20% today with increasing volume on a ~$2M market cap. That’s not normal.

Recent updates picking up + KeepZone AI just got authorization in energy/infrastructure security.

Early narrative forming. High risk, but watching closely

[Dr. Pat Soon-Shiong @DrPatrick]

Global expansion-first approval in Asia!! Anktiva now approved in Macau, China today. Paradigm change of treating the immune system unstoppable.

[Dr. Pat Soon-Shiong @DrPatrick]

Pleased with the NCCN guidelines for Papillary only disease in non-muscle invasive bladder cancer (NMIBC). Validates the publication in Journal of Urology.

Now next step is to provide BCG for all patients who could benefit in bladder cancer.

https://t.co/8I5cBG0M3k

[Camus @newstart_2024]

Dr. Patrick Soon-Shiong just showed Chris Cuomo dramatic before-and-after brain scans of late-stage tumor patients who failed chemo, radiation, and surgery — achieving complete remission with ANKTIVA.

No chemo. No radiation. Tumors shrinking dramatically in months.

He says: “We got FDA approval to treat patients who failed everything… and they got complete remissions. It wasn’t a one-off anecdote.”

ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist that activates and proliferates natural killer cells and CD8+ T-cells while avoiding regulatory T-cell suppression, turning the immune system into a targeted cancer-killing force.

Clip from this 43-second segment — a potential game-changer for late-stage cases.

Is ANKTIVA the breakthrough we’ve been waiting for… or do we need larger trials to confirm?

Your thoughts — drop them below.

Stay informed. Stay hopeful.

[Dr. Pat Soon-Shiong @DrPatrick]

As I reflect on the Cuomo special on “ Why have we not cured Cancer” I marvel and am so encouraged by the candid and honest comments made by Jay, Tony and Peter that night. I had never met either @JayBattachary nor @DrTonyLetai nor Peter the former FDA asst Commisioner until the Chris Cuomo show on Friday night. I was so so inspired by their statements during the live show and will highlight what they shared with the audience and the American public. It was so encouraging to me that we have new NIH and NCI leadership and ( past) FDA leadership who understands the issues that would have major impact on our country, affecting patients with cancer and even longevity. That the intersection of the advances in Science and innovation and Regulatory Policy is needed to keep Americans healthy and in fact is the essence of MAHA. And that science matters.

Most importantly the commitment by Chris Cuomo to host a show that allows detailed, honest civil discussion of the most important issues that face our nation. No other station has aired such a show and allowed the American public to be part of the conversation as important and devastating as cancer. I remain grateful to Chris and the executives at NewsNation for creating such a unique show. And for Chris asking the right ( and difficult often unspoken) questions. Lots still to answer..I hope more shows like this to come.

The candid and insightful statements that were shared with the public by Jay, Tony and Peter included:

1. The real progress made in the field of immunotherapy

2.The inadequacies at the current FDA bureaucracy levels of one division not recognizing what another division has already affirmed and keeping up with the rapid evolution of scientific advances that affect the health of the American people especially the desperate patients with cancer who have failed all standards of care.

3. The inconsistencies between approval of single arm trials when it is applied to big pharma for essentially the same immunotherapy field and when the indication was approved across multiple tumor types based on single arm trials

4 The remarks by the former FDA Assistant Commisioner that FDA policy has already established that the Mechanism of Action if affirmed aligns with ability for this mechanism to be asserted across suplemental indications

5. And perhaps most importantly the NIH director who affirmed that the “ Plausible Mechanism of Action” just announced by FDA is indeed the path to expedite access of life saving drugs to the American public. I was so heartened by this statement, since this was the case I have tried to make to the FDA at my multiple visits to DC- that the plausible mechanism of action that the FDA published in the NEJM as the modernized pathway should apply to IL-15. Especially since the mechanism of activating NK and T cells and memory T cells with IL-15 was affirmed by the NCI itself as far back as 2007 and then re-affirmed by the FDA itself in the approved Anktiva label for bladder cancer. So beyond “ plausible” and in fact affirmed! See section 12.1 of the package insert for those interested.

I will find each of these video segments and post them as NewsNation releases the You Tube full video today. More to come as Chris said at the end of the show. Thanks NewsNation and thanks Chris for opening up this conversation on cancer for transparency to the public and exposing the machinations and obstacles behind the scenes!!

[100xOG @100xOG]

@DrPatrick Big step forward, especially considering the unmet need in this space. Long-term outcomes and broader adoption will be key, but the momentum is encouraging.

[100xOG @100xOG]

@DrPatrick Big step forward, especially considering the unmet need in this space. Long-term outcomes and broader adoption will be key, but the momentum is encouraging.

[Dr. Pat Soon-Shiong @DrPatrick]

So here is the logic. Anktiva (IL-15) was ranked number ONE to cure cancer. Keytruda was ranked number TWO by NCI in 2007. Anktiva GROWS T CELLS. Keytruda takes the BRAKES OFF THE T CELLS.

Eventually Keytruda fails since there are no T cells to take the brakes off. So if T cells could be replenished by GROWING T CELLS WITHIN YOUR BODY AS THE FACTORY and STIMULATED WITH IL-15 by growing T crlls together with NK cells, Keytruda can be rescued and allow T cells to work again and prolong life.

Well that is EXACTLY what we showed in our lung cancer trials and our trial with over 10 different tumor types and presented this data to Saudi FDA… resulting in approval of Anktiva in combination with Keytruda to prolong lives of patients with lung cancer who had failed all standards of care and whose tumors were spreading and growing while on Keytruda!

So in short the combination of number 1 with number 2 ranked molecules of the immune system is both biologically rational and logical based on their MECHANISMS OF ACTION. And last night @DrJBhattacharya mentioned loudly that FDA wants to accelerate approvals based on their doctrine of “plausible mechanism of action”. Anktiva’s mechanism has been validated by FDA themselves within the approved package insert!

With regard to single arm trials: Number two ranked drug developed over last decade (with 40 FDA approvals and approved for multiple tumor types with SINGLE ARM TRIALS FOR MSI high for Merck). So when combined with the Number ONE ranked drug to rescue the number two, then magic happens. But it’s not magic… it’s the biology of your immune system… NK cells rescue T cells. The single arm trial with very mature data was accepted by Saudi FDA to enable their population to have access to this combination.

This is the enlightenment that is needed!

https://t.co/lh0frZJrD8